Sponsored by Novalix
For too long, DNA-encoded libraries (DEL) have been viewed primarly as as a number game. At Novalix, we take a different approach: DEL screening is a powerful way to identify valuable drug-like hits, amenable for optimization by medicinal chemists to fuel the next generation of drug candidates.
In this webinar, we will demonstrate how thoughtful design, high-quality standards in library synthesis, and strategic use of AI/ML models propels DEL as a valuable tool for hit identification and expansion.
Two case studies will be presented relying on these pillars and making the difference. The first one will show the potential of harnessing the synergy of DEL and PROTAC technologies to quickly deliver PROTAC degraders. The second case study will illustrate the power of DEL screening, combined with AI/ML to achieve excellent starting points for drug discovery projects.
Learning Objectives:
· The design and synthesis of high-fidelity drug-like DNA-encoded libraries
· Using AI/ML models trained on large DEL datasets to identify novel chemotypes
· Applications of these technologies in drug discovery
Privacy Policy
In 2017, Miguel transitioned into the field of DNA-encoded libraries (DEL), taking on project management
responsibilities and developing deep expertise in this technology. Today, with 10 years of experience in DEL, he serves as Associate Director of DNA-Encoded Libraries at Novalix, where he leads and oversees library synthesis.
